The ASCO Post

🚨 Leadership Update at @AmericanCancer & @ACSCAN: Shane Jacobson named incoming CEO, effective Aug 12, 2025, succeeding interim CEO Dr. Wayne A.I. Frederick, MD, MBA Details on Jacobson’s background & strategic vision: ascopost.com/news/july-2025… #ACSCAN #ACS

In the July issue of The ASCO Post are highlights from the recent #ASCO25 plenary sessions, #EHA2025, #PrevConf25 as well as professional and patient reflections. Read the full issue here: ascopost.com/issues/july-25…

A phase III trial found no benefit for regional nodal irradiation in pts with node-positive #BreastCancer who became ypN0 after #NeoadjuvantChemotherapy. 5-yr survival outcomes were comparable. Lead: Eleftherios Mamounas, MD, MPH ➡️ ascopost.com/news/june-2025…

🔬 Translational data from #POETIC suggest short-term hormonal therapy may help guide treatment decisions in ER+/HER2+ breast cancer 🧬 Subtype shifts after 2 weeks linked to prognosis & treatment response 🔷 @MaggieCheang ➡️ ascopost.com/news/july-2025…

🩺 Final OS results from the phase III #FLAURA2 trial show significant survival benefit with osimertinib + chemo vs monotherapy in 1L EGFR-mutant #NSCLC 👨‍⚕️ Led by Dr. Pasi A. Jänne of @DanaFarber 🔗 ascopost.com/news/july-2025… #LungCancer #OncologyResearch #EGFR

CBO Report – NIH Cuts Threaten Innovation A new CBO analysis warns that proposed NIH budget cuts could slow new drug development by 20+ fewer approvals per decade. Insights from @LLacasseACSCAN 🔗 ascopost.com/news/july-2025… #HealthPolicy @NIH @USCBO

📈U.S. alcohol-associated cancer deaths doubled from 1990 to 2021 Biggest impact: 🔹Men 🔹Adults 55+ 🔹Washington DC 🔹Liver, colorectal, esophageal cancers 🗣️ Insights from @Jani_Chinmay + @jsparano 🔗ascopost.com/news/july-2025… #Oncology #CancerAwareness

📈Analysis of metastatic urothelial cancer trends showed a 44% relative improvement in long-term survival with contemporary treatments of immune checkpoint inhibitors and antibody-drug conjugates. 🔬Research from @Ron_cology ascopost.com/news/july-2025… #UrothelialCancer

📢 New guidelines support guided bronchoscopy for lung cancer biomarker testing, showing comparable sample quality to percutaneous biopsy with fewer complications. 🩺 With commentary from: @Re_innervated 🔗 ascopost.com/news/july-2025… #LungCancer #BiomarkerTesting #Pulmonology

🩺 Phase III data from #STAMPEDE platform showed no significant survival benefit with adding #Metformin in metastatic hormone-sensitive #ProstateCancer ⚖️Metformin did reduce #WeightGain and metabolic side effects from #ADT 👩‍⚕️ @Silke_Gillessen 🔗 ascopost.com/news/july-2025…

#AIinOncology: Researchers from @MSKCancerCenter used ChatGPT-4 to classify pancreatic cysts from imaging with 97-99% accuracy vs radiologist reads. 👨‍⚕️ @KevinCSoaresMD 🔗 ascopost.com/news/july-2025… #Radiology #PancreaticCancer

In a population-based study of women with early #BreastCancer, aprepitant use during chemo was linked to improved outcomes in TNBC: ➡️ 34% reduced risk of distant recurrence ➡️ 39% reduced risk of breast cancer–related death @MIPS_Australia @JNCI 🔗ascopost.com/news/july-2025…

📊 Researchers found no clear link between oral contraceptive use and #LiverCancer risk, though a slight increase was observed with longer-term use. ✍️Cody Watling, DPhil; corresponding author: Katherine McGlynn, PhD @TheLancetOncology 🔗 ascopost.com/news/july-2025…

A 90-day preoperative endocrine “test run” helped women w/ ER+ early breast cancer & their surgeons alter adjuvant RT plans. 🔄 28% changed RT preference 👩‍⚕️ 24% change in MD rec Presenter: @shaynalefrak Comments: @puneetsinghmd #Deescalation #ASBrS2025 🔗 ascopost.com/issues/june-25…

In 3-year follow-up from phase III TRANSFORM trial, 2L liso-cel showed sustained benefit vs SOC in R/R LBCL: ➡️ EFS: 29.5 mo vs 2.4 mo ➡️ PFS: NR vs 6.2 mo ➡️ OS trended better despite 66% crossover —Manali Kamdar, MD, MBBS, et al #Lymphoma #CARTcell 🔗 ascopost.com/news/july-2025…

Real-world data confirm safety for teclistamab in patients with RRMM, even those not eligible for MajesTEC-1. One-year OS rate 61%. Study by Beatrice Razzo, MD, et al. #MMsm #BCMA 🔗 ascopost.com/news/july-2025…

📬 Real-world randomized study showed mailed HPV self-collection kits + reminders doubled cervical cancer screenings for under-screened women vs reminders alone (41% vs 17%). ✍️Jane Montealegre, PhD, MPH, et al #CervicalCancer #HPV #CancerPrevention 🔗 ascopost.com/issues/june-25…

In resectable NSCLC 🫁, 18-month distant metastasis–free survival rate was ~80% with perioperative chemoimmunotherapy, per retrospective study. Outcomes similar across neoadjuvant/adjuvant use. Study by @ADesaiMD et al 🔗ascopost.com/news/july-2025… #LCSM #NSCLC #Immunotherapy

Obesity-related cancer deaths in US have nearly tripled since 1999, with steepest rises in older adults, rural regions, and Midwest. New data from @TheEndoSociety highlights disparities. 📈 Study led by Faizan Ahmed, MD: ascopost.com/news/july-2025… #Oncology #ObesityAwareness #ENDO25

📈Literature review by @DrKimmieNg et al finds a 14.8% rise in incidence of early-onset GI cancers (2010–2019) with highest increases seen in <40 age group 📊 #CancerResearch #GIoncology 🔗ascopost.com/news/july-2025…